SCHEMBL2480796

SCHEMBL2480796

CN1CCC(Nc2ccc(S(=O)(=O)N(Oc3ccc4[nH]ccc4c3)C(=O)c3ccccc3)cc2[N+](=O)[O-])CC1

nearest known ligand 0.47

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 1/20 0.45
ALDH3A1 P30838 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17419440 0.89 BCL2 (0.45) BCL2
SCHEMBL2507853 0.86 ALDH3A1 (0.42) ALDH3A1
SCHEMBL1958806 0.84 ALDH3A1 (0.45) BCL2ALDH3A1
SCHEMBL1957676 0.81 BCL2 (0.47) BCL2
SCHEMBL1956186 0.81 BCL2 (0.49) BCL2
SCHEMBL1957515 0.79 BCL2 (0.61) BCL2
SCHEMBL30314083 0.79 BCL2 (0.61) BCL2
SCHEMBL2506487 0.76 BCL2 (0.42) BCL2
SCHEMBL1742890 0.76 MAPT (0.43)
SCHEMBL1744608 0.75 SLC6A2 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376480-A2 SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES Abbott Laboratories (US) 2011-10-19 EP claimed
WO-2010065865-A2 BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-06-10 WO claimed
EP-2376480-A2 SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES Abbott Laboratories (US) 2011-10-19 EP disclosed
WO-2010065865-A2 BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES ABBOTT LABORATORIES (US) 2010-06-10 WO disclosed